On Thursday, weight loss drug giant Novo Nordisk held a earnings conference call, promising to further adopt a price reduction strategy in the US market. The company's Chief Financial Officer, Karsten Munk Knudsen, stated that due to huge sales and fierce competition, Novo Nordisk plans to lower the price of its weight loss drug Wegovy in the United States.